Psychiatr. pro Praxi, 2006; 6: 297-299

Atypický obraz neuroleptického maligního syndromu

MUDr. Martin Hýža, MUDr. Vlasta Hanušková
Psychiatrická léčebna Opava

Uvedená kazuistika se věnuje rozboru atypického obrazu a průběhu neuroleptického maligního syndromu. Atypičnost spočívala v neúplně vyjádřených příznacích s absencí tremoru, kolísání vegetativních funkcí a febrilií. K plnému vyjádření extrapyramidového syndromu došlo pozvolna v průběhu cca 1 týdne, zároveň s uzavřením ORL diagnózy flegmona submandibulární krajiny. NMS jsme léčili aktivně infuzemi dantrolenu a denní aplikací elektrokonvulzivní terapie (ECT) s uspokojivým efektem, po 10 konvulzích jsme museli přerušit pro mohutný vzestup myoglobinémie. Diskutovány jsou možné příčiny. Ze zkušeností vyplývá zásadní postavení ECT v terapeutických postupech.

Published: February 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hýža M, Hanušková V. Atypický obraz neuroleptického maligního syndromu. Psychiatr. praxi. 2006;7(6):297-299.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andreassen MD, Pedersen S. [Malignant neuroleptic syndrome. A review of epidemiology, risk factors, diagnosis, differential diagnosis and pathogenesis of MNS] Ugeskr Laeger. 2000 Mar 6; 162 (10): 1366-1370. Go to PubMed...
    2. Bhave CG, Gadre KC, Gharpure BS. Myoglobinuria following the use of succinylcholine. J Postgrad Med. 1993 Jul-Sep; 39 (3): 157-159.
    3. Davis JM, Janicak PG, Sakkas P, Gilmore C, Wang Z. Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. Convuls Ther. 1991; 7 (2): 111-120.
    4. Gerbershagen MU, Ito WD, Wappler F, Fiege M, Schulte am Esch J. [Malignant neuroleptic syndrome after haloperidol administration] Anaesthesist. 2001 May; 50 (5): 329-332. Go to original source... Go to PubMed...
    5. Hadad E, Weinbroum AA, Ben-Abraham R. Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med. 2003 Jun; 10 (2): 149-154. Go to original source... Go to PubMed...
    6. Hall RC, Appleby B, Hall RC. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J. 2005 Jan; 98 (1): 114-117. Go to original source... Go to PubMed...
    7. Kasantikul D, Kanchananakhin P. Severe catatonia and neuroleptic malignant syndrome: report of 3 cases. J Med Assoc Thai. 1999 Sep; 82 (9): 942-946. Go to PubMed...
    8. Nyquist OG. [What do we know today about neuroleptic malignant syndrome] Tidsskr Nor Laegeforen. 1996 Oct 10; 116 (24): 2879-2882. Go to PubMed...
    9. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry. 1992 Jun; 160: 868.
    10. Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991; 27 (3): 381-384. Go to PubMed...
    11. Saunders BP, Trewby PN. The neuroleptic malignant syndrome: a missed diagnosis? Br J Clin Pract. 1993 May-Jun; 47 (3): 170-171. Go to original source... Go to PubMed...
    12. Seifertová D. Maligní neuroleptický syndrom In: Höschl C, Libiger J, Švestka J (ed.) Psychiatrie. Tigis 2002: 751-756.
    13. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999 Oct; 33 (5): 650-659. Go to original source... Go to PubMed...
    14. Werawatganon T, Kyokong O, Charuluxananan S, Punyatavorn S. Muscular injury after succinylcholine and electroconvulsive therapy. Anesth Analg. 2004 Jun; 98 (6): 1674-1675. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.